(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 31.97% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.63%.
Exagen's revenue in 2023 is $45,415,000.On average, 3 Wall Street analysts forecast XGN's revenue for 2023 to be $978,075,874, with the lowest XGN revenue forecast at $871,460,659, and the highest XGN revenue forecast at $1,077,086,208.
In 2024, XGN is forecast to generate $1,101,565,440 in revenue, with the lowest revenue forecast at $1,101,565,440 and the highest revenue forecast at $1,101,565,440.